Lyell Immunopharma, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Lyell Immunopharma (market cap ~$129M) reported Q2 2026 net loss of $44.8M (vs. $42.7M YoY), with R&D expenses rising $4.7M to $39.5M due to increased clinical trial activity. Cash position of $228.0M (down $19.2M from Dec 2025) provides runway into Q3 2027. Lead program ronde-cel (dual CD19/CD20 CAR-T for LBCL) showed safety improvements (no Grade ≥3 CRS in 100+ patients, 97% manufacturing success); PiNACLE pivotal trial on track for mid-2027 data and H2 2027 BLA submission. Secondary program LYL273 (GCC-targeted CAR-T for mCRC) amended to Phase 1/2 design after GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% to 10%.
Why this rating
Clinical progress (safety/efficacy) and extended cash runway support near-term milestones; rising burn ($44.8M quarterly) against modest cash represents meaningful runway risk within 12–18 months without partnership/financing.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.